Panasonic teams up with 7X Paralympic Champion Hannah Cockroft for Paris 2024 Paralympic Games
Celebrating the countdown to the Paris 2024 Paralympic Games, Worldwide Olympic and Paralympic Partner Panasonic joins forces with the Team England wheelchair racing 7-time Paralympic Champion and 12-time World Champion, Hannah Cockroft to promote environmental sustainability on a global scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230831059501/en/
Hannah Cockroft (Photo: Business Wire)
Since its founding, Panasonic has been committed to making positive contributions to the world and society. It has set ambitious targets to create a positive impact on environmental sustainability under its Panasonic GREEN IMPACT initiative. Hannah will join Team Panasonic as an ambassador focused on sustainability and inclusivity while receiving support from the company on her journey to her fourth Paralympic Games.
After picking up wheelchair racing at a talent day at Loughborough University in October 2007, Hannah has blazed a trail straight to legend status. As one of the most successful para-athletes in recent times, Hannah is looking forward to continuing to inspire people all over the world to embrace the Paralympic movement and celebrate inclusion.
Besides her tremendous athletic achievements, Hannah was one of 50+ Tokyo Olympians and Paralympians from 35 different countries, who took part in the Athletes of the World campaign which challenged World Leaders about the urgent need for ambitious climate action.
She is additionally using her platform to make a difference in issues beyond the sports arena, such as working with federations to reduce the use of single-use plastics. Panasonic is looking forward to working together with her on similar projects and initiatives that epitomise Panasonic’s core values of Contribution to Society, Cooperation & Team Spirit, and Untiring Effort & Improvement.
Hannah Cockroft comments, “It is a privilege to have Panasonic supporting me as I head into the Paris 2024 Paralympic Games. The backing and promotion to a wider audience will help me retain my top performing athlete position and enable me in turn to champion the need for climate change action, and increased inclusivity on a wider scale.”
Panasonic Champions the Champions
Panasonic has supported the Olympic and Paralympic Movements and their Athletes for nearly four decades. Several world-class athletes have been part of its Team Panasonic extended family. These athletes are committed to breaking barriers, improving communities, and bringing awareness to important issues such as sustainability, diversity, and inclusivity, and Hannah is no exception.
Junichi Suzuki, Chairman and CEO of Panasonic Europe B.V. comments, “Hannah’s focus on societal change, including being a patron and ambassador for several charities that enable her to encourage others to get active, alongside her participation in the sustainability initiatives, embodies the spirit of Team Panasonic.
We are proud to welcome her to the Team Panasonic family and have her be part of our team to shine a light on global climate change initiatives and innovations that tackle the world’s most pressing environmental problems.”
For more information about Panasonic GREEN IMPACT vision visit: https://www.panasonic.com/uk/corporate/sustainability.html
For more information about Panasonic as a Worldwide Olympic and Paralympic Partner visit: Panasonic Official Olympic & Paralympic Website| Panasonic Holdings
About the Panasonic Group
Founded in 1918, and today a global leader in developing innovative technologies and solutions for wide-ranging applications in the consumer electronics, housing, automotive, industry, communications, and energy sectors worldwide, the Panasonic Group switched to an operating company system on April 1, 2022 with Panasonic Holdings Corporation serving as a holding company and eight companies positioned under its umbrella. The Group reported consolidated net sales of 8,378.9 billion yen (ca. 59.4 billion Euro) for the year ended March 31, 2023.
To learn more about the Panasonic Group, please visit: https://holdings.panasonic/global/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230831059501/en/
Contact information
Tanya Houston, Wildwood Plus, tanya.houston@wildwoodplus.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom